Has Perrigo Become the Perfect Stock?

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Every investor would love to stumble upon the perfect stock. But will you ever really find a stock that provides everything you could possibly want?

One thing's for sure: You'll never discover truly great investments unless you actively look for them. Let's discuss the ideal qualities of a perfect stock, then decide if Perrigo (NYSE: PRGO  ) fits the bill.

The quest for perfection
Stocks that look great based on one factor may prove horrible elsewhere, making due diligence a crucial part of your investing research. The best stocks excel in many different areas, including these important factors:

  • Growth. Expanding businesses show healthy revenue growth. While past growth is no guarantee that revenue will keep rising, it's certainly a better sign than a stagnant top line.
  • Margins. Higher sales mean nothing if a company can't produce profits from them. Strong margins ensure that company can turn revenue into profit.
  • Balance sheet. At debt-laden companies, banks and bondholders compete with shareholders for management's attention. Companies with strong balance sheets don't have to worry about the distraction of debt.
  • Money-making opportunities. Return on equity helps measure how well a company is finding opportunities to turn its resources into profitable business endeavors.
  • Valuation. You can't afford to pay too much for even the best companies. By using normalized figures, you can see how a stock's simple earnings multiple fits into a longer-term context.
  • Dividends. For tangible proof of profits, a check to shareholders every three months can't be beat. Companies with solid dividends and strong commitments to increasing payouts treat shareholders well.

With those factors in mind, let's take a closer look at Perrigo.


What We Want to See


Pass or Fail?


5-year annual revenue growth > 15%




1-year revenue growth > 12%




Gross margin > 35%




Net margin > 15%



Balance sheet

Debt to equity < 50%




Current ratio > 1.3




Return on equity > 15%




Normalized P/E < 20




Current yield > 2%




5-year dividend growth > 10%




Total score


6 out of 10

Source: S&P Capital IQ. Total score = number of passes.

Since we looked at Perrigo last year, the company has added a point, with gross margins climbing slightly. The stock's performance has been reasonably good, with Perrigo posting about a 10% gain over the past year.

Perrigo makes generic drugs. That's been a lucrative market especially in the past year or two, as some massive blockbuster drugs have come off-patent, making them available for generic-makers to duplicate and sell. Yet Perrigo definitely doesn't have the market to itself, with giant Teva Pharmaceutical (NYSE: TEVA  ) and quick-growing Watson Pharmaceuticals (NYSE: AGN  ) being just a couple of its main competitors.

Still, Perrigo combines several favorable traits. It has a huge pipeline, with dozens of drugs submitted to the Food and Drug Administration for review, and has released approved versions at a respectable pace. For instance, in October, it got FDA approval for a drug similar to GlaxoSmithKline's (NYSE: GSK  ) Nicorette to help smokers quit. Moreover, its margins are top-notch, with the company topping Teva's formerly industry-leading profit margin over the past year despite Teva's huge size advantage.

One area of controversy involves so-called "pay for delay" arrangements that help Perrigo earn some extra revenue. In November, Perrigo settled lawsuits with Cadence Pharmaceuticals (NASDAQ: CADX  ) to put off marketing a generic version of its Ofirmex drug in exchange for rights to market an authorized generic in about seven years. Some believe the arrangements are anticompetitive, and the Supreme Court is expected to take up the antitrust issues this year.

For Perrigo to improve, it needs to get margins up just a bit further and then focus on getting debt paid down. Mix that with richer dividends, and Perrigo could look a lot more like a perfect stock in the near future.

Keep searching
No stock is a sure thing, but some stocks are a lot closer to perfect than others. By looking for the perfect stock, you'll go a long way toward improving your investing prowess and learning how to separate out the best investments from the rest.

What's inside Supernova?
If you're an investor looking for big long-term winners, Motley Fool co-founder David Gardner's picks have frequently trounced the market. How? Because he's always on the lookout for revolutionary stocks and recommends them before Wall Street catches on to their disruptive potential. If you're interested in how David discovers his winners, click here to get instant access to a personal tour behind David's Supernova service.

Click here to add Perrigo to My Watchlist, which can find all of our Foolish analysis on it and all your other stocks.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2179208, ~/Articles/ArticleHandler.aspx, 10/9/2015 8:29:13 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Dan Caplinger

Dan Caplinger has been a contract writer for the Motley Fool since 2006. As the Fool's Director of Investment Planning, Dan oversees much of the personal-finance and investment-planning content published daily on With a background as an estate-planning attorney and independent financial consultant, Dan's articles are based on more than 20 years of experience from all angles of the financial world.

Today's Market

updated 11 hours ago Sponsored by:
DOW 17,050.75 138.46 0.82%
S&P 500 2,013.43 17.60 0.88%
NASD 4,810.79 19.64 0.41%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/8/2015 4:00 PM
PRGO $158.34 Up +2.22 +1.42%
Perrigo Company CAPS Rating: ****
AGN $276.16 Up +7.17 +2.67%
Allergen PLC CAPS Rating: ****
CADX $0.00 Down +0.00 +0.00%
Cadence Pharmaceut… CAPS Rating: **
GSK $40.16 Up +0.44 +1.11%
GlaxoSmithKline CAPS Rating: ****
TEVA $59.24 Up +0.69 +1.18%
Teva Pharmaceutica… CAPS Rating: ****